Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia
January 7, 2021
Previous PostMedinCell announces the transfer of its shares from compartment C to compartment B of Euronext Paris
Next PostMedinCell announces the resume of listing of its shares on Euronext Paris as of the opening of the stock exchange tomorrow
